ENTERA BIO LTD. Restricted Cash and Cash Equivalents
ENTERA BIO LTD. (ENTX) had Restricted Cash and Cash Equivalents of $7.22 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-08-07
- 2026-06-30: Restricted Cash and Cash Equivalents $7.22M.
- 2026-03-31: Restricted Cash and Cash Equivalents $7.88M.
- 2025-12-31: Restricted Cash and Cash Equivalents $7.78M.
- 2025-09-30: Restricted Cash and Cash Equivalents $8.11M.
| Period end | Restricted Cash and Cash Equivalents | Restricted Cash and Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $7.22M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $7.88M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $7.78M 10-K · filed 2026-03-27 | |
| 2025-09-30 | $8.11M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $8.10M 10-Q · filed 2026-08-07 | |
| 2025-03-31 | $8.09M 10-Q · filed 2026-05-08 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-27 | $80.00K 10-K · filed 2025-03-28 |
| 2024-09-30 | $78.00K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $78.00K 10-Q · filed 2025-08-08 | |
| 2024-03-31 | $64.00K 10-Q · filed 2025-05-09 | |
| 2023-12-31 | $66.00K 10-K · filed 2025-03-28 | |
| 2023-09-30 | $91.00K 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $66.00K 10-Q · filed 2024-08-09 | |
| 2023-03-31 | $65.00K 10-Q · filed 2024-05-10 | |
| 2022-12-31 | $67.00K 10-K · filed 2024-03-08 | |
| 2022-09-30 | $67.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $37.00K 10-Q · filed 2023-08-11 | |
| 2022-03-31 | $40.00K 10-Q · filed 2023-05-05 | |
| 2021-12-31 | $72.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $70.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $70.00K 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $70.00K 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $70.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |